PANTHERx Rare Partners with Chiesi as Exclusive Distributor for Oral Acromegaly Treatment MYCAPSSA
Key Insights
PANTHERx Rare (search) has been selected as the exclusive specialty pharmacy to distribute MYCAPSSA (octreotide), an oral somatostatin analog for acromegaly (search) maintenance treatment.
The partnership aims to improve patient access and support for individuals with acromegaly (search), a rare condition caused by growth hormone overproduction from pituitary adenomas.
MYCAPSSA is indicated for long-term maintenance treatment in acromegaly (search) patients who have previously responded to and tolerated octreotide or lanreotide therapy.
PANTHERx Rare (search), a specialty pharmacy focused exclusively on rare and orphan diseases, has been selected by Chiesi (search) as the exclusive distributor for MYCAPSSA (octreotide), an oral treatment for acromegaly (search) patients. The partnership, announced on October 13, 2025, is designed to enhance patient access and support for individuals living with this rare endocrine disorder.
Addressing Unmet Needs in Acromegaly Treatment
MYCAPSSA is an oral somatostatin analog indicated for the long-term maintenance treatment of acromegaly (search) patients who have responded to and tolerated treatment with octreotide or lanreotide. The medication works by decreasing growth hormone production associated with acromegaly, offering patients an oral alternative to injectable therapies.
Acromegaly (search) is a rare condition that occurs from the overproduction of growth hormone by the pituitary gland, most commonly caused by a benign tumor on the gland called a pituitary adenoma (search). The condition presents with varied symptoms including enlarged hands, feet, and facial features, thickened and oily skin, increased sweating, deeper voice, headaches, and joint aches.
The complications of acromegaly (search) can be severe and include type 2 diabetes (search), high blood pressure, heart disease, sleep apnea, arthritis, and other conditions affecting the bones and muscles. Current treatment options may include surgery to remove the pituitary tumor, medications, and radiation therapy.
Strategic Partnership for Rare Disease Access
"We are pleased to partner with Chiesi (search) to distribute MYCAPSSA and support people living with acromegaly (search)," said Bansi Nagji, CEO of PANTHERx Rare (search). "At PANTHERx, our mission is clear: to stand with individuals and families affected by rare diseases. Those in the acromegaly community often face access challenges and limited treatment options, and it is our responsibility—and our privilege—to provide the right treatment, tools, and personalized support they deserve."
PANTHERx Rare (search) operates as a dual-accredited specialty pharmacy with notable distinctions in rare diseases, including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence. The company has received recognition as an eight-time winner of the prestigious MMIT Patient Choice Award, including the 2025 honor.
Safety Profile and Clinical Considerations
MYCAPSSA carries important safety considerations that require careful monitoring. The medication can cause problems with the gallbladder, requiring periodic patient monitoring and discontinuation if complications of cholelithiasis are suspected. Healthcare providers must monitor blood sugar, thyroid levels, and vitamin B12 levels and treat accordingly.
Cardiovascular effects including bradycardia, arrhythmia, or conduction abnormalities may occur, potentially requiring adjustment of treatment with drugs that have bradycardia effects. Gastrointestinal effects such as new onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs.
The most common adverse reactions with an incidence greater than 10% include nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.
Expanding Access Through Specialized Distribution
The partnership leverages PANTHERx Rare (search)'s specialized infrastructure for rare disease medications. The company is headquartered in Pittsburgh, Pennsylvania and is licensed in all 50 states and U.S. territories, providing comprehensive geographic coverage for MYCAPSSA distribution.
Chiesi (search) Global Rare Diseases, the business unit responsible for the partnership, is established to deliver innovative therapies and solutions for people affected by rare diseases. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the healthcare system, with a goal of ensuring equal access so as many people as possible can experience their most fulfilling life.